


# Reengineering the antimicrobial peptide from the scorpion venom of *Opisthacanthus madagascariensis* into highly active peptides with low toxicity

Cyntia S Oliveira, Cibele N Pedron, Viviane B Andrade, Gislaine P Andrade, Giselle Cerchiaro, Pedro I Silva Jr, Fernanda D Silva, Vani X Oliveira Jr

## Introduction

The poisons have several bioactive molecules and they are therefore considered a potential source of new drugs. In this work, we reprogrammed the cationic amphipathic antimicrobial peptide (AMP) IsCT1, derived from the scorpion venom *Opisthacanthus madagascariensis*, seeking to reduce the toxicity to human cells and enhance its intrinsic antimicrobial properties. In this attempt, synthetic variants with a net charge ranging from +3 to +6 were generated through the simultaneous replacement of 1 to 4 amino acid residues in the original sequence positions, resulting in 6 scorpion-derived antimicrobial peptide IsCT1.




**Figure 1.** Helical wheel projections of IsCT1 and its analogs. Yellow, green and grey circles indicate hydrophobic amino acids, blue, purple and red, represent hydrophilic amino acids.

**Table 1.** Peptide sequence, molecular weight and physicochemical properties


Peptide	Sequence	Molecular Weight (Da)		Purity (%)	H	μH	P/N	z
		Calculated	Observed					
IsCT1-NH <sub>2</sub>	H <sub>3</sub> N <sup>+</sup> -ILGKIWEGIKSLF-CONH <sub>2</sub>	1501.9	1503.0	98	0.783	0.776	0.857	+2
[P] <sup>7</sup> -IsCT1-NH <sub>2</sub>	H <sub>3</sub> N <sup>+</sup> -ILGKFWPGIKSLF-CONH <sub>2</sub>	1469.9	1472.0	98	0.888	0.674	0.625	+3
[K] <sup>7</sup> [P] <sup>8</sup> -IsCT1-NH <sub>2</sub>	H <sub>3</sub> N <sup>+</sup> -ILKKIWEPIKSLF-CONH <sub>2</sub>	1613.0	1614.9	99	0.762	0.827	0.857	+3
[A] <sup>1</sup> [K] <sup>2</sup> [F] <sup>3</sup> [K] <sup>8</sup> -IsCT1-NH <sub>2</sub>	H <sub>3</sub> N <sup>+</sup> -ALKKFWKIKSLF-CONH <sub>2</sub>	1582.0	1583.9	98	0.515	0.801	0.623	+4
[A] <sup>1</sup> [F] <sup>2</sup> [P] <sup>3</sup> [K] <sup>8</sup> -IsCT1-NH <sub>2</sub>	H <sub>3</sub> N <sup>+</sup> -ALGKFWPKIKSLF-CONH <sub>2</sub>	1532.9	1533.8	99	0.696	0.676	0.623	+4
[K] <sup>2</sup> [K] <sup>7</sup> [K] <sup>8</sup> -IsCT1-NH <sub>2</sub>	H <sub>3</sub> N <sup>+</sup> -ILKKIWKGKSLF-CONH <sub>2</sub>	1587.0	1588.0	95	0.465	0.642	1.167	+6
[K] <sup>2</sup> [K] <sup>7</sup> [P] <sup>8</sup> [K] <sup>9</sup> -IsCT1-NH <sub>2</sub>	H <sub>3</sub> N <sup>+</sup> -ILKKIWKPKSLF-CONH <sub>2</sub>	1627.1	1628.0	99	0.521	0.650	0.857	+6

H: hydrophobicity; μH: hydrophobic moment; P/N: polar – nonpolar residues proportion; z: net charge




**Figure 2.** Circular dichroism spectra of the peptides in water, PBS, SDS (20 mmol L<sup>-1</sup>), TFE Water (60%). The peptide concentrations were 40.0 μmol L<sup>-1</sup>.

## Results




**Figure 3.** Antimicrobial of IsCT1 and analogs. Antimicrobial activity expressed as MIC (Minimal inhibitory concentration). The concentration range of the peptides was 64.0 to 1.0 μmol L<sup>-1</sup>.




**Figure 4.** Antitumoral and Cytotoxicity of IsCT1 and analogs. Activity expressed as percentage of viable cells by peptide concentration (range of the peptides was 128.0 – 1.0 μmol L<sup>-1</sup>).

**Figure 5.** Hemolytic activities of IsCT1 and analogs. The concentration range of the peptides was 128 – 0.1 μmol L<sup>-1</sup>.



**Figure 6.** Degradation resistance assays of IsCT1 and its analogs in fetal bovine serum. Analyses were performed at 0, 0.5, 1, 2, 4 and 6 h.



## Discussion and conclusion

The resulting synthetic peptides showed increased antimicrobial activity against Gram-positive bacteria (*Staphylococcus aureus* and *Staphylococcus epidermidis*) and Gram-negative bacteria (*Enterobacter cloacae*, *Escherichia coli*, *Klebsiella oxytoca* and *Pseudomonas aeruginosa*) and provoked a decreasing in the hemolytic activity compared to the native molecule. Glutamic acid (position 7) was shown to be important in the interaction with the erythrocyte membrane, with a reduction in hemolysis when replaced by another amino acid residue. It was also observed that several peptides have anti-cancer activity due to their ability to target the human breast cancer cell line MCF-7, without activity against healthy cell line MCF-10A. In general, we show a mutation-based approach to manipulate the peptide structure influencing its biological function, enabling new therapeutic properties.

## Acknowledgements